Frequency of Smad gene mutations in human cancers - PubMed (original) (raw)
. 1997 Jul 1;57(13):2578-80.
Affiliations
- PMID: 9205057
Frequency of Smad gene mutations in human cancers
G J Riggins et al. Cancer Res. 1997.
Abstract
Much excitement has recently been generated by the discovery of the Smad genes, encoding proteins that transduce signals from the transforming growth factor beta family of cytokines. Here, we report the completion of cloning of the six known human Smads, providing novel sequences for Smad5 and Smad6. Previously, Smad4 and Smad2 were shown to be mutated in human cancers. However, analysis of the other four Smad genes revealed no mutations in a total of 167 tumors, including those from colon, breast, lung, and pancreas. These results suggest that the various Smad genes have different functions and demonstrate that mutations in these four genes do not, in general, account for the widespread resistance to transforming growth factor beta that is found in human tumors.
Similar articles
- Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7 genes in colorectal cancer.
Fukushima T, Mashiko M, Takita K, Otake T, Endo Y, Sekikawa K, Takenoshita S. Fukushima T, et al. J Exp Clin Cancer Res. 2003 Jun;22(2):315-20. J Exp Clin Cancer Res. 2003. PMID: 12866583 - Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4.
Morén A, Itoh S, Moustakas A, Dijke P, Heldin CH. Morén A, et al. Oncogene. 2000 Sep 7;19(38):4396-404. doi: 10.1038/sj.onc.1203798. Oncogene. 2000. PMID: 10980615 - TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines.
Fink SP, Mikkola D, Willson JK, Markowitz S. Fink SP, et al. Oncogene. 2003 Mar 6;22(9):1317-23. doi: 10.1038/sj.onc.1206128. Oncogene. 2003. PMID: 12618756 - Functions of mammalian Smad genes as revealed by targeted gene disruption in mice.
Weinstein M, Yang X, Deng C. Weinstein M, et al. Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):49-58. doi: 10.1016/s1359-6101(99)00028-3. Cytokine Growth Factor Rev. 2000. PMID: 10708952 Review. - [Genetic variation of insulin-like growth factor binging proteins and tumorigenesis].
Lu WH, Lai MD. Lu WH, et al. Zhonghua Bing Li Xue Za Zhi. 2012 May;41(5):351-5. doi: 10.3760/cma.j.issn.0529-5807.2012.05.016. Zhonghua Bing Li Xue Za Zhi. 2012. PMID: 22883679 Review. Chinese. No abstract available.
Cited by
- SMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR + HER2- breast cancer.
Li K, Shu D, Li H, Lan A, Zhang W, Tan Z, Huang M, Tomasi ML, Jin A, Yu H, Shen M, Liu S. Li K, et al. Cell Death Dis. 2024 Jun 24;15(6):444. doi: 10.1038/s41419-024-06838-9. Cell Death Dis. 2024. PMID: 38914552 Free PMC article. - The Role of the Transforming Growth Factor-β Signaling Pathway in Gastrointestinal Cancers.
Matsuoka T, Yashiro M. Matsuoka T, et al. Biomolecules. 2023 Oct 19;13(10):1551. doi: 10.3390/biom13101551. Biomolecules. 2023. PMID: 37892233 Free PMC article. Review. - The Synergistic Cooperation between TGF-β and Hypoxia in Cancer and Fibrosis.
Mallikarjuna P, Zhou Y, Landström M. Mallikarjuna P, et al. Biomolecules. 2022 Apr 25;12(5):635. doi: 10.3390/biom12050635. Biomolecules. 2022. PMID: 35625561 Free PMC article. Review. - Targeting TGF-β signal transduction for fibrosis and cancer therapy.
Peng D, Fu M, Wang M, Wei Y, Wei X. Peng D, et al. Mol Cancer. 2022 Apr 23;21(1):104. doi: 10.1186/s12943-022-01569-x. Mol Cancer. 2022. PMID: 35461253 Free PMC article. Review. - Matriptase-2/NR4A3 axis switches TGF-β action toward suppression of prostate cancer cell invasion, tumor growth, and metastasis.
Lin HY, Ko CJ, Lo TY, Wu SR, Lan SW, Huang CA, Lin YC, Lin HH, Tu HF, Lee CF, Hsiao PW, Huang HP, Chen MJ, Chang KH, Lee MS. Lin HY, et al. Oncogene. 2022 May;41(20):2833-2845. doi: 10.1038/s41388-022-02303-z. Epub 2022 Apr 13. Oncogene. 2022. PMID: 35418692
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous